Concept to Claims: The Patented Side of My Science
7+ patents covering cancer therapeutics, immunology, and drug discovery. Cancer therapies are undergoing a seismic shift with patents emerging that unlock new molecular vulnerabilities. Among the most promising are compounds designed to disable WRN helicase, a DNA repair enzyme uniquely essential to cancers exhibiting microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). These inventions strike at the heart of tumor survival while sparing healthy cells, offering hope in settings where immunotherapies or chemotherapy resistance prevail. Alongside these inhibitors, novel antibody approaches targeting mutant calreticulin extend the toolkit of selective, mechanism-driven cancer therapeutics.
- WRN Helicase Inhibitors: Oncology patents targeting WRN helicase, a synthetic lethal vulnerability in MSI-high and dMMR cancers. Structure-guided inhibitors offering selective therapy for colorectal, endometrial, and gastric tumors.
- Mutant CalR Targeted Antibodies: Therapeutic antibodies targeting mutant calreticulin in myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis. Structure-based design enables selective targeting of malignant cells while sparing normal tissue.
- Innovative Structure-Enabled Drug Discovery: Structure-guided discovery platforms integrating X-ray crystallography, cryo-EM, and computational design to enable rational drug development for difficult-to-drug targets in oncology and immunology.
Top Patents
